Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis

Biochemistry

Volumn 48, Issue 7, 2009, Pages 1474-1480

  Dhar, Rohini ^a   Persaud, Shalini D ^a   Mireles, Joe R ^a   Basu, Alakananda ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A549 CELLS; APOPTOSIS; CALPAIN; CASPASE INHIBITORS; CASPASE-3; CELL-CYCLE PROGRESSIONS; CELL-PERMEABLE PEPTIDES; CISPLATIN; CONCENTRATION DEPENDENTS; DNA DAMAGES; DNA-DAMAGING AGENTS; DRUG RESISTANCES; ECTOPIC EXPRESSIONS; IN-VITRO; INDUCED APOPTOSIS; MCF-7 CELLS; N TERMINALS; NON-SMALL-CELL LUNG CANCERS; PROTEIN TRANSLATIONS; PROTEOLYTIC CLEAVAGES; RECOGNITION SITES; S6 KINASE; SITE-DIRECTED MUTAGENESIS; SMALL CELL LUNG CANCERS;

AMINES; BIOLOGICAL ORGANS; CELL DEATH; DNA; DRUG PRODUCTS; GENES; GLYCOSYLATION; NUCLEIC ACIDS;

PLATINUM COMPOUNDS;

CALPASTATIN; CASPASE 3; CASPASE INHIBITOR; CISPLATIN; DNA; PROTEASOME; S6 KINASE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; DNA DAMAGE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; DRUG EFFECT; GENETICS; HYDROLYSIS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; DNA; DNA DAMAGE; HUMANS; HYDROLYSIS; LUNG NEOPLASMS; MUTAGENESIS, SITE-DIRECTED; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA;

EID: 61749096079     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi801840s     Document Type: Article

References (40)

1. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. (1997) Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16 (12), 3693-3704.
2. Barlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., and Bittner, M. L. (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 92 (15), 1252-1292.
3. Dhar, R., and Basu, A. (2008) Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. Int. J. Oncol. 32 (5), 1133-1137.
4. Klos, K. S., Wyszomierski, S. L., Sun, M., Tan, M., Zhou, X., and Li, P. (2006) ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 66 (4), 2028-2037.
5. Liu, L. Z., Zhou, X. D., Qian, G., Shi, X., Fang, J., and Jiang, B. H. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 67 (13), 6325-6332.
6. Seufferlein, T., and Rozengurt, E. (1996) Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 56 (17), 3895-3897.
7. Cohen, G. M. (1997) Caspases: The executioners of apoptosis. Biochem. J. 326, 1-16.
8. Nicholson, D. W. (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6 (11), 1028-1042.
9. Salvesen, G. S., and Dixit, V. M. (1999) Caspase activation: The induced-proximity model. Proc. Natl. Acad. Sci. U.S.A. 96, 10964-10967.
10. Baliga, B. C., Read, S. H., and Kumar, S. (2004) The biochemical mechanism of caspase-2 activation. Cell Death Differ. 11 (11), 1234-1241.
11. Duan, H., and Dixit, V. M. (1997) RAIDD is a new 'death' adaptor molecule. Nature 385 (6611), 86-89.
12. Tinel, A., and Tschopp, J. (2004) The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304 (5672), 843-846.
13. Fuentes-Prior, P., and Salvesen, G. S. (2004) The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 384 (Part 2), 201-232.
14. Salvesen, G S., and Dixit, V. M. (1997) Caspases: Intracellular signaling by proteolysis. Cell 91 (4), 443-446.
15. Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O'Reilly, T., et al. (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (6), 747-759.
16. Grunwald, V., DeGraffenried, L., Russel, D., Friedrichs, W. E., Ray, R. B., and Hidalgo, M. (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62 (21), 6141-6145.
17. Mabuchi, S., Altomare, D. A., Cheung, M., Zhang, L., Poulikakos, P. I., Hensley, H. H., et al. (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. 13 (14), 4261-4270.
18. Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., and Mills, G. B. (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 55 (9), 1982-1988.
19. Wan, X., and Helman, L. J. (2002) Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 4 (5), 400-408.
20. Wu, C., Wangpaichitr, M., Feun, L., Kuo, M. T., Robles, C., and Lampidis, T. (2005) Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol. Cancer 4 (1), 25-34.
21. Calastretti, A., Rancati, F., Ceriani, M. C., Asnaghi, L., Canti, G., and Nicolin, A. (2001) Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur. J. Cancer 37 (16), 2121-2128.
22. Law, M., Forrester, E., Chytil, A., Corsino, P., Green, G., Davis, B., et al. (2006) Rapamycin disrupts cyclin/cyclin-dependent kinase/ p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res. 66 (2), 1070-1080.
23. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68, 383-424.
24. Fischer, U., Janicke, R. U., and Schulze-Osthoff, K. (2003) Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ. 10 (1), 76-100.
25. Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., and Garcia-Calvo, M. (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272 (29), 17907-17911.
26. Stennicke, H. R., Renatus, M., Meldal, M., and Salvesen, G S. (2000) Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem. J. 350 (Part 2), 563-568.
27. Jahani-Asl, A., Basak, A., and Tsang, B. K (2007) Caspase-3-mediated cleavage of Akt: Involvement of non-consensus sites and influence of phosphorylation. FEBS Lett. 581 (16), 2883-2888.
28. Cheng, E. H., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., et al. (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278 (5345), 1966-1968.
29. Morley, S. J., Jeffrey, I., Bushell, M., Pain, V. M., and Clemens, M. J. (2000) Differential requirements for caspase-8 activity in the mechanism of phosphorylation of eIF2a, cleavage of eIF4GI and signaling events associated with the inhibition of protein synthesis in apoptotic Jurkat T cells. FEBS Lett. 477 (3), 229-236.
30. Timmer, J. C., and Salvesen, G S. (2007) Caspase substrates. Cell Death Differ. 14 (1), 66-72.
31. Luthi, A. U., and Martin, S. J. (2007) The CASBAH: A searchable database of caspase substrates. Cell Death Differ. 14 (4), 641-650.
32. Utz, P. J., and Anderson, P. (2000) Life and death decisions: Regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ. 7 (7), 589-602.
33. Riedl, S. J., and Shi, Y. (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 5 (11), 897-907.
34. Talanian, R. V., Quinlan, C., Trautz, S., Hackett, M. C., Mankovich, J. A., Banach, D., et al. (1997) Substrate specificities of caspase family proteases. J. Biol. Chem. 272 (15), 9677-9682.
35. Butkinaree, C., Cheung, W. D., Park, S., Park, K., Barber, M., and Hart, G W. (2008) Characterization of β-N-Acetylglucosaminidase Cleavage by Caspase-3 during Apoptosis. J. Biol. Chem. 283 (35), 23557-23566.
36. Kipp, M., Schwab, B. L., Przybylski, M., Nicotera, P., and Fackelmayer, F. O. (2000) Apoptotic cleavage of scaffold attachment factor A (SAF-A) by caspase-3 occurs at a noncanonical cleavage site. J. Biol. Chem. 275 (7), 5031-5036.
37. Lee, M. W., Hirai, I., and Wang, H. G (2003) Caspase-3-mediated cleavage of Rad9 during apoptosis. Oncogene 22 (41), 6340-6346.
38. Basu, A., Lu, D., Sun, B., Moor, A. N., Akkaraju, G R., and Huang, J. (2002) Proteolytic activation of protein kinase C-epsilon by caspase-mediated processing and transduction of antiapoptotic signals. J. Biol. Chem. 277 (44), 41850-41856.
39. Lu, D., Huang, J., and Basu, A. (2006) Protein kinase Cε activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-a-induced cell death. J. Biol. Chem. 281 (32), 22799-22807.
40. Mahalingam, M., and Templeton, D. J. (1996) Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains. Mol. Cell. Biol. 16 (1), 405-413.